Arch Biopartners Inc. ACHFF
Set alert
0.58 USD -0.01 -0.85%
At close · Oct 30
0.5768 Day range 0.62
0.299 52-week range 0.995
- YTD
- -34.31%
- 1 year
- -17.14%
- Open
- 0.6195
- Prev close
- 0.585
- Mkt cap
- 39.40M
- Vol
- 7.60K
- Avg vol
- 19.71K
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.5768
- High
- 0.62
- Earnings
- Jan 29, 2024
Next earnings
Jan 29, 2024
Expected Jan 29, 2024. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 29, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| Jan 29, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
News
- Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
- Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
- Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
- Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
- Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
- Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
- Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Your note
Sign in to keep a note on ACHFF — it syncs with the Stock Master app.